Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study
In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and ag...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2012-01, Vol.30 (3), p.291-299 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 299 |
|---|---|
| container_issue | 3 |
| container_start_page | 291 |
| container_title | Journal of clinical oncology |
| container_volume | 30 |
| creator | VAN DER KAAIJ, Marleen A. E HEUTTE, Natacha ALEMAN, Berthe M. P NOORDIJK, Evert M FERME, Christophe THOMAS, José STAMATOULLAS, Aspasia FRUCHART, Christophe BRICE, Pauline GAILLARD, Isabelle BOLOGNA, Serge ONG, Francisca MEIJNDERS, Paul EGHBALI, Houchingue DOORDUIJN, Jeanette K MORSCHHAUSER, Franck SEBBAN, Catherine ROESINK, Judith M BOUTELOUP, Marie VAN HOOF, Achiel RAEMAEKERS, John M. M HERTRY-AMAR, Michel KLUIN-NELEMANS, Hanneke C ABEILARD-LEMOISSON, Edwige SPINA, Michele MOSER, Elizabeth C ALLGEIER, Anouk MEULEMANS, Bart SIMONS, Arnold H. M LUGTENBURG, Pieternella J |
| description | In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment.
The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Étude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis.
Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF.
Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF. |
| doi_str_mv | 10.1200/JCO.2011.37.1989 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02358987v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1008847918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-6a6a593ffa8a64c6ef1c868ebf7ba3490c793c050c1bd218cd041caf1e0d00173</originalsourceid><addsrcrecordid>eNp9ksGO0zAQhiMEYpfCnRPyBRUOKXacxMneqmq7BVUqYovEzZo6k8ZLEhc7Keoj8Fy8Bg-D05bCiZPHo2_-Gc38QfCS0QmLKH33YbaaRJSxCRcTlmf5o-CaJZEIhUiSx8E1FTwKWca_XAXPnHuglMUZT54GV1HEspiL6Dr49dFiA11vkaz2YDW0ZA66Hv7QFmSOttO17g5Et2Rp2m24RtuQ-97u9d5YR0xJFqbYftXt2JHlodlVpoEbMiW3vTU79HIru4VWO-i0aUlpLPmEDsGq6thgbRG6BttuUJpBq9BeZMidNf3uiB0jJMX454-uL3yAl24-8ol6PC36ukMyM5WxHbn32OF58KSE2uGL8zsKPs9v17NFuFzdvZ9Nl6GKU9GFKaSQ5LwsIYM0VimWTGVphptSbIDHOVUi54omVLFN4TenChozBSVDWvidCj4K3p50K6jlzuoG7EEa0HIxXcohRyOeZHkm9syz4xO7s-Zbj66TjXYK6xpaNL2TORMsEYLHnnzzX5JRmmWxyP2BRwE9ocoa5yyWlykYlYNTpHeKHJwiuZCDU3zJq7N6v2mwuBT8sYYHXp8BcArq0vrjaPeXSxIWxfE_XKW31XdtUboG6trLRvJBGU4ll1HO-G9Tg9Yh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1008847918</pqid></control><display><type>article</type><title>Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>VAN DER KAAIJ, Marleen A. E ; HEUTTE, Natacha ; ALEMAN, Berthe M. P ; NOORDIJK, Evert M ; FERME, Christophe ; THOMAS, José ; STAMATOULLAS, Aspasia ; FRUCHART, Christophe ; BRICE, Pauline ; GAILLARD, Isabelle ; BOLOGNA, Serge ; ONG, Francisca ; MEIJNDERS, Paul ; EGHBALI, Houchingue ; DOORDUIJN, Jeanette K ; MORSCHHAUSER, Franck ; SEBBAN, Catherine ; ROESINK, Judith M ; BOUTELOUP, Marie ; VAN HOOF, Achiel ; RAEMAEKERS, John M. M ; HERTRY-AMAR, Michel ; KLUIN-NELEMANS, Hanneke C ; ABEILARD-LEMOISSON, Edwige ; SPINA, Michele ; MOSER, Elizabeth C ; ALLGEIER, Anouk ; MEULEMANS, Bart ; SIMONS, Arnold H. M ; LUGTENBURG, Pieternella J</creator><creatorcontrib>VAN DER KAAIJ, Marleen A. E ; HEUTTE, Natacha ; ALEMAN, Berthe M. P ; NOORDIJK, Evert M ; FERME, Christophe ; THOMAS, José ; STAMATOULLAS, Aspasia ; FRUCHART, Christophe ; BRICE, Pauline ; GAILLARD, Isabelle ; BOLOGNA, Serge ; ONG, Francisca ; MEIJNDERS, Paul ; EGHBALI, Houchingue ; DOORDUIJN, Jeanette K ; MORSCHHAUSER, Franck ; SEBBAN, Catherine ; ROESINK, Judith M ; BOUTELOUP, Marie ; VAN HOOF, Achiel ; RAEMAEKERS, John M. M ; HERTRY-AMAR, Michel ; KLUIN-NELEMANS, Hanneke C ; ABEILARD-LEMOISSON, Edwige ; SPINA, Michele ; MOSER, Elizabeth C ; ALLGEIER, Anouk ; MEULEMANS, Bart ; SIMONS, Arnold H. M ; LUGTENBURG, Pieternella J</creatorcontrib><description>In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment.
The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Étude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis.
Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF.
Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2011.37.1989</identifier><identifier>PMID: 22184372</identifier><language>eng</language><publisher>Alexandria, VA: American Society of Clinical Oncology</publisher><subject>Adolescent ; Adult ; Biological and medical sciences ; Cancer ; Cohort Studies ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Europe ; Female ; Fertility ; Follow-Up Studies ; Hematologic and hematopoietic diseases ; Hodgkin Disease - complications ; Hodgkin Disease - pathology ; Hodgkin Disease - therapy ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Life Sciences ; Medical sciences ; Multicenter Studies as Topic ; Primary Ovarian Insufficiency - etiology ; Randomized Controlled Trials as Topic ; Surveys and Questionnaires ; Survivors ; Tumors ; Young Adult</subject><ispartof>Journal of clinical oncology, 2012-01, Vol.30 (3), p.291-299</ispartof><rights>2015 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-6a6a593ffa8a64c6ef1c868ebf7ba3490c793c050c1bd218cd041caf1e0d00173</citedby><cites>FETCH-LOGICAL-c467t-6a6a593ffa8a64c6ef1c868ebf7ba3490c793c050c1bd218cd041caf1e0d00173</cites><orcidid>0000-0002-3714-9824 ; 0000-0002-7993-4046 ; 0000-0002-1620-6105</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3716,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25512442$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22184372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02358987$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>VAN DER KAAIJ, Marleen A. E</creatorcontrib><creatorcontrib>HEUTTE, Natacha</creatorcontrib><creatorcontrib>ALEMAN, Berthe M. P</creatorcontrib><creatorcontrib>NOORDIJK, Evert M</creatorcontrib><creatorcontrib>FERME, Christophe</creatorcontrib><creatorcontrib>THOMAS, José</creatorcontrib><creatorcontrib>STAMATOULLAS, Aspasia</creatorcontrib><creatorcontrib>FRUCHART, Christophe</creatorcontrib><creatorcontrib>BRICE, Pauline</creatorcontrib><creatorcontrib>GAILLARD, Isabelle</creatorcontrib><creatorcontrib>BOLOGNA, Serge</creatorcontrib><creatorcontrib>ONG, Francisca</creatorcontrib><creatorcontrib>MEIJNDERS, Paul</creatorcontrib><creatorcontrib>EGHBALI, Houchingue</creatorcontrib><creatorcontrib>DOORDUIJN, Jeanette K</creatorcontrib><creatorcontrib>MORSCHHAUSER, Franck</creatorcontrib><creatorcontrib>SEBBAN, Catherine</creatorcontrib><creatorcontrib>ROESINK, Judith M</creatorcontrib><creatorcontrib>BOUTELOUP, Marie</creatorcontrib><creatorcontrib>VAN HOOF, Achiel</creatorcontrib><creatorcontrib>RAEMAEKERS, John M. M</creatorcontrib><creatorcontrib>HERTRY-AMAR, Michel</creatorcontrib><creatorcontrib>KLUIN-NELEMANS, Hanneke C</creatorcontrib><creatorcontrib>ABEILARD-LEMOISSON, Edwige</creatorcontrib><creatorcontrib>SPINA, Michele</creatorcontrib><creatorcontrib>MOSER, Elizabeth C</creatorcontrib><creatorcontrib>ALLGEIER, Anouk</creatorcontrib><creatorcontrib>MEULEMANS, Bart</creatorcontrib><creatorcontrib>SIMONS, Arnold H. M</creatorcontrib><creatorcontrib>LUGTENBURG, Pieternella J</creatorcontrib><title>Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment.
The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Étude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis.
Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF.
Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Cohort Studies</subject><subject>Disease-Free Survival</subject><subject>Dose-Response Relationship, Drug</subject><subject>Europe</subject><subject>Female</subject><subject>Fertility</subject><subject>Follow-Up Studies</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hodgkin Disease - complications</subject><subject>Hodgkin Disease - pathology</subject><subject>Hodgkin Disease - therapy</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Life Sciences</subject><subject>Medical sciences</subject><subject>Multicenter Studies as Topic</subject><subject>Primary Ovarian Insufficiency - etiology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Surveys and Questionnaires</subject><subject>Survivors</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ksGO0zAQhiMEYpfCnRPyBRUOKXacxMneqmq7BVUqYovEzZo6k8ZLEhc7Keoj8Fy8Bg-D05bCiZPHo2_-Gc38QfCS0QmLKH33YbaaRJSxCRcTlmf5o-CaJZEIhUiSx8E1FTwKWca_XAXPnHuglMUZT54GV1HEspiL6Dr49dFiA11vkaz2YDW0ZA66Hv7QFmSOttO17g5Et2Rp2m24RtuQ-97u9d5YR0xJFqbYftXt2JHlodlVpoEbMiW3vTU79HIru4VWO-i0aUlpLPmEDsGq6thgbRG6BttuUJpBq9BeZMidNf3uiB0jJMX454-uL3yAl24-8ol6PC36ukMyM5WxHbn32OF58KSE2uGL8zsKPs9v17NFuFzdvZ9Nl6GKU9GFKaSQ5LwsIYM0VimWTGVphptSbIDHOVUi54omVLFN4TenChozBSVDWvidCj4K3p50K6jlzuoG7EEa0HIxXcohRyOeZHkm9syz4xO7s-Zbj66TjXYK6xpaNL2TORMsEYLHnnzzX5JRmmWxyP2BRwE9ocoa5yyWlykYlYNTpHeKHJwiuZCDU3zJq7N6v2mwuBT8sYYHXp8BcArq0vrjaPeXSxIWxfE_XKW31XdtUboG6trLRvJBGU4ll1HO-G9Tg9Yh</recordid><startdate>20120120</startdate><enddate>20120120</enddate><creator>VAN DER KAAIJ, Marleen A. E</creator><creator>HEUTTE, Natacha</creator><creator>ALEMAN, Berthe M. P</creator><creator>NOORDIJK, Evert M</creator><creator>FERME, Christophe</creator><creator>THOMAS, José</creator><creator>STAMATOULLAS, Aspasia</creator><creator>FRUCHART, Christophe</creator><creator>BRICE, Pauline</creator><creator>GAILLARD, Isabelle</creator><creator>BOLOGNA, Serge</creator><creator>ONG, Francisca</creator><creator>MEIJNDERS, Paul</creator><creator>EGHBALI, Houchingue</creator><creator>DOORDUIJN, Jeanette K</creator><creator>MORSCHHAUSER, Franck</creator><creator>SEBBAN, Catherine</creator><creator>ROESINK, Judith M</creator><creator>BOUTELOUP, Marie</creator><creator>VAN HOOF, Achiel</creator><creator>RAEMAEKERS, John M. M</creator><creator>HERTRY-AMAR, Michel</creator><creator>KLUIN-NELEMANS, Hanneke C</creator><creator>ABEILARD-LEMOISSON, Edwige</creator><creator>SPINA, Michele</creator><creator>MOSER, Elizabeth C</creator><creator>ALLGEIER, Anouk</creator><creator>MEULEMANS, Bart</creator><creator>SIMONS, Arnold H. M</creator><creator>LUGTENBURG, Pieternella J</creator><general>American Society of Clinical Oncology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-3714-9824</orcidid><orcidid>https://orcid.org/0000-0002-7993-4046</orcidid><orcidid>https://orcid.org/0000-0002-1620-6105</orcidid></search><sort><creationdate>20120120</creationdate><title>Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study</title><author>VAN DER KAAIJ, Marleen A. E ; HEUTTE, Natacha ; ALEMAN, Berthe M. P ; NOORDIJK, Evert M ; FERME, Christophe ; THOMAS, José ; STAMATOULLAS, Aspasia ; FRUCHART, Christophe ; BRICE, Pauline ; GAILLARD, Isabelle ; BOLOGNA, Serge ; ONG, Francisca ; MEIJNDERS, Paul ; EGHBALI, Houchingue ; DOORDUIJN, Jeanette K ; MORSCHHAUSER, Franck ; SEBBAN, Catherine ; ROESINK, Judith M ; BOUTELOUP, Marie ; VAN HOOF, Achiel ; RAEMAEKERS, John M. M ; HERTRY-AMAR, Michel ; KLUIN-NELEMANS, Hanneke C ; ABEILARD-LEMOISSON, Edwige ; SPINA, Michele ; MOSER, Elizabeth C ; ALLGEIER, Anouk ; MEULEMANS, Bart ; SIMONS, Arnold H. M ; LUGTENBURG, Pieternella J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-6a6a593ffa8a64c6ef1c868ebf7ba3490c793c050c1bd218cd041caf1e0d00173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Cohort Studies</topic><topic>Disease-Free Survival</topic><topic>Dose-Response Relationship, Drug</topic><topic>Europe</topic><topic>Female</topic><topic>Fertility</topic><topic>Follow-Up Studies</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hodgkin Disease - complications</topic><topic>Hodgkin Disease - pathology</topic><topic>Hodgkin Disease - therapy</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Life Sciences</topic><topic>Medical sciences</topic><topic>Multicenter Studies as Topic</topic><topic>Primary Ovarian Insufficiency - etiology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Surveys and Questionnaires</topic><topic>Survivors</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAN DER KAAIJ, Marleen A. E</creatorcontrib><creatorcontrib>HEUTTE, Natacha</creatorcontrib><creatorcontrib>ALEMAN, Berthe M. P</creatorcontrib><creatorcontrib>NOORDIJK, Evert M</creatorcontrib><creatorcontrib>FERME, Christophe</creatorcontrib><creatorcontrib>THOMAS, José</creatorcontrib><creatorcontrib>STAMATOULLAS, Aspasia</creatorcontrib><creatorcontrib>FRUCHART, Christophe</creatorcontrib><creatorcontrib>BRICE, Pauline</creatorcontrib><creatorcontrib>GAILLARD, Isabelle</creatorcontrib><creatorcontrib>BOLOGNA, Serge</creatorcontrib><creatorcontrib>ONG, Francisca</creatorcontrib><creatorcontrib>MEIJNDERS, Paul</creatorcontrib><creatorcontrib>EGHBALI, Houchingue</creatorcontrib><creatorcontrib>DOORDUIJN, Jeanette K</creatorcontrib><creatorcontrib>MORSCHHAUSER, Franck</creatorcontrib><creatorcontrib>SEBBAN, Catherine</creatorcontrib><creatorcontrib>ROESINK, Judith M</creatorcontrib><creatorcontrib>BOUTELOUP, Marie</creatorcontrib><creatorcontrib>VAN HOOF, Achiel</creatorcontrib><creatorcontrib>RAEMAEKERS, John M. M</creatorcontrib><creatorcontrib>HERTRY-AMAR, Michel</creatorcontrib><creatorcontrib>KLUIN-NELEMANS, Hanneke C</creatorcontrib><creatorcontrib>ABEILARD-LEMOISSON, Edwige</creatorcontrib><creatorcontrib>SPINA, Michele</creatorcontrib><creatorcontrib>MOSER, Elizabeth C</creatorcontrib><creatorcontrib>ALLGEIER, Anouk</creatorcontrib><creatorcontrib>MEULEMANS, Bart</creatorcontrib><creatorcontrib>SIMONS, Arnold H. M</creatorcontrib><creatorcontrib>LUGTENBURG, Pieternella J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAN DER KAAIJ, Marleen A. E</au><au>HEUTTE, Natacha</au><au>ALEMAN, Berthe M. P</au><au>NOORDIJK, Evert M</au><au>FERME, Christophe</au><au>THOMAS, José</au><au>STAMATOULLAS, Aspasia</au><au>FRUCHART, Christophe</au><au>BRICE, Pauline</au><au>GAILLARD, Isabelle</au><au>BOLOGNA, Serge</au><au>ONG, Francisca</au><au>MEIJNDERS, Paul</au><au>EGHBALI, Houchingue</au><au>DOORDUIJN, Jeanette K</au><au>MORSCHHAUSER, Franck</au><au>SEBBAN, Catherine</au><au>ROESINK, Judith M</au><au>BOUTELOUP, Marie</au><au>VAN HOOF, Achiel</au><au>RAEMAEKERS, John M. M</au><au>HERTRY-AMAR, Michel</au><au>KLUIN-NELEMANS, Hanneke C</au><au>ABEILARD-LEMOISSON, Edwige</au><au>SPINA, Michele</au><au>MOSER, Elizabeth C</au><au>ALLGEIER, Anouk</au><au>MEULEMANS, Bart</au><au>SIMONS, Arnold H. M</au><au>LUGTENBURG, Pieternella J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2012-01-20</date><risdate>2012</risdate><volume>30</volume><issue>3</issue><spage>291</spage><epage>299</epage><pages>291-299</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment.
The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Étude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis.
Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF.
Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF.</abstract><cop>Alexandria, VA</cop><pub>American Society of Clinical Oncology</pub><pmid>22184372</pmid><doi>10.1200/JCO.2011.37.1989</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3714-9824</orcidid><orcidid>https://orcid.org/0000-0002-7993-4046</orcidid><orcidid>https://orcid.org/0000-0002-1620-6105</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2012-01, Vol.30 (3), p.291-299 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02358987v1 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Biological and medical sciences Cancer Cohort Studies Disease-Free Survival Dose-Response Relationship, Drug Europe Female Fertility Follow-Up Studies Hematologic and hematopoietic diseases Hodgkin Disease - complications Hodgkin Disease - pathology Hodgkin Disease - therapy Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Life Sciences Medical sciences Multicenter Studies as Topic Primary Ovarian Insufficiency - etiology Randomized Controlled Trials as Topic Surveys and Questionnaires Survivors Tumors Young Adult |
| title | Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T21%3A52%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Premature%20Ovarian%20Failure%20and%20Fertility%20in%20Long-Term%20Survivors%20of%20Hodgkin's%20Lymphoma:%20A%20European%20Organisation%20for%20Research%20and%20Treatment%20of%20Cancer%20Lymphoma%20Group%20and%20Groupe%20d'%C3%89tude%20des%20Lymphomes%20de%20l'Adulte%20Cohort%20Study&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=VAN%20DER%20KAAIJ,%20Marleen%20A.%20E&rft.date=2012-01-20&rft.volume=30&rft.issue=3&rft.spage=291&rft.epage=299&rft.pages=291-299&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2011.37.1989&rft_dat=%3Cproquest_hal_p%3E1008847918%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1008847918&rft_id=info:pmid/22184372&rfr_iscdi=true |